BST Position Update – October 23, 2015

| October 23, 2015

BST Position Update

. . . .  Xenor (NASD: $XNCR) – Hold

Xenor has just initiated Phase 2 clinical trial of a biological candidate using XmAb Cytotoxix Fc domain for the treatment of asthma and allergic diseases.

Xenor has narrowed their current quarter loss from 21 cents a share to 17 cents a share. We are seeing solid performance from this company.

The original buy price was $8.56 and its current price is $12.03. My buy up to price is $9.40 so we will continue to hold this stock as I have a feeling we could see more profits.

Continue to hold XNCR.

. . . .  Threshold Pharmaceuticals (NASDAQ: $THLD) – Buy

Threshold Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) have issued two U.S. patents protecting Tarloxotinib, the company’s proprietary hypoxia-activated, irreversible epidermal growth receptor. This drug is used to treat non-small cell lung cancer.

The current price is $3.90 and my buy up to price is $4.80. There is still time to profit with THLD if you haven’t already bought it…

. . . . Aeterna Zentariss (NASDAQ: $AEZS) – Sell

Aeterna is just not doing good.

The company was hit with a class action shareholders lawsuit.

They are trying to regroup.  And we’re cutting this stock out of our portfolio.

Sell AEZS now.

Action To Take

  • Hold XCNR
  • Buy THLD
  • Sell AEZS

Category: BST Update

About the Author ()

Comments are closed.

«
»